Amplia Therapeutics (ASX:ATX) Net Margin %: 0.00% (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.14
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Net Margin %?

Amplia Therapeutics ASX:ATX +8.00% 36 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Amplia Therapeutics ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Amplia Therapeutics's Net Income for the six months ended in Mar. 2026 was A$-3.53 Mil. Amplia Therapeutics's Revenue for the six months ended in Mar. 2026 was A$0.00 Mil. Therefore, Amplia Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Amplia Therapeutics's Net Margin % or its related term are showing as below:


ASX:ATX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Amplia Therapeutics  (ASX:ATX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Amplia Therapeutics Net Margin % Related Terms

Amplia Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Net Margin % Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ATX vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Amplia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Net Margin % falls into.


ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Amplia Therapeutics's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin=Net Income (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-7.707/0
= %

Amplia Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.531/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Amplia Therapeutics (ASX:ATX) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Amplia Therapeutics and its competitors. According to the industry distribution chart, Amplia Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry.
Is Amplia Therapeutics' Net Margin % too high?
Amplia Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Amplia Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #999999 out of 947 companies for Net Margin %. This places Amplia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price